Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

  • October 2017 •
  • 488 pages •
  • Report ID: 5256002 •
  • Format: PDF
DISEASE OVERVIEW
Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

MARKET SNAPSHOT
Modest market growth will be driven by label expansions and new launches, but will be moderated by genericization of Revlimid and Velcade.
Velcade and Revlimid dominate early treatment settings, but are replaced by newer drugs as patients relapse and become refractory to treatment.
The incident population is forecast to undergo a substantial 41% increase from 56,770 cases in 2016 to 80,290 in 2036.
The approvals of Empliciti and Darzalex could dramatically change the treatment of MM, as they represent much-needed new treatment options for relapsed MM patients.
Keytruda has an extensive development program and promising early-phase data in multiple myeloma.
Multiple myeloma drugs will enjoy reimbursement by US payers for the foreseeable future, while novel combinations will spur risk sharing in Europe.